A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in adulthood

Trial Profile

A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in adulthood

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Langerhans cell histiocytosis; Medulloblastoma; Neuroblastoma; Retinoblastoma; Solid tumours; Wilms' tumour
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Accural started at in July 2017 and 26 patients were enrolled up to July 2018, Scheduled recruitment period is 18 months as per trial design presented at 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Trial design presented at 54th Annual Meeting of the American Society of Clinical Oncology.
    • 30 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top